Bibliometric evaluation of research trends and hotspots concerning the interaction between immune checkpoint inhibitors and glioma.

INTRODUCTION: Immune checkpoint inhibitors have revolutionized oncology, but their efficacy in glioma remains a major focus of research. This study employs bibliometric methods to analyze the current research status and emerging trends in the field of Immune Checkpoint Inhibitors and Glioma, providing a reference for subsequent research in this domain. METHODS: This study retrieve articles related to Immune Checkpoint Inhibitors and Glioma from the WOS Core Database, covering the period from the database's inception to April 9, 2025. Following rigorous selection criteria, employ VOSviewer and CiteSpace to conduct analyses on quantity, collaboration networks, clustering, and citation bursts. RESULTS: The number of publications concerning Immune Checkpoint Inhibitors and Glioma has been increasing annually, with a significant surge post-2017. China leads in publication volume, while the United States has the highest citation count. Harvard Medical School stands out as both the institution with the highest number of publications and citations. Among the top ten journals with the most publications, seven are classified in the Q1 category of the JCR. The most cited article is "Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial" by Reardon DA et al., published in 2020 in JAMA ONCOLOGY. The ten most frequently occurring keywords include glioma, immunotherapy, glioblastoma, expression, cancer, central nervous system, prognosis, blockade, survival, and T-cells. The keyword cluster "cuproptosis" has emerged as a novel area of focus in recent years, whereas oncolytic virotherapy remains a current research hotspot. CONCLUSION: This study employs bibliometric analysis to elucidate publication trends in the domain of Immune Checkpoint Inhibitors and Glioma, examining the collaborative networks among countries, institutions, and authors. It further identifies recent research hotspots, thereby providing an objective data-driven reference for scientific inquiry into Immune Checkpoint Inhibitors and Glioma.